Entia Biosciences (ERGO) stock price, revenue, and financials

Entia Biosciences market cap is $1.1 m, and annual revenue was $265.47 k in FY 2016

$1.1 M

ERGO Mkt cap, 09-Sept-2021

$265.5 K

Entia Biosciences Revenue FY, 2016
Entia Biosciences Revenue growth (FY, 2015 - FY, 2016), %(23%)
Entia Biosciences Gross profit (FY, 2016)174 K
Entia Biosciences Gross profit margin (FY, 2016), %65.5%
Entia Biosciences Net income (FY, 2016)-1.4 M
Entia Biosciences EBIT (FY, 2016)-1.3 M
Entia Biosciences Cash, 31-Dec-201676.1 K
Entia Biosciences EV1.1 M
Get notified regarding key financial metrics and revenue changes at Entia BiosciencesLearn more
Banner background

Entia Biosciences Revenue

Entia Biosciences revenue was $265.47 k in FY, 2016 which is a 23.5% year over year decrease from the previous period.

Embed Graph

Entia Biosciences Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

403.3k369.3k314.7k656.3k346.9k265.5k

Revenue growth, %

109%(47%)(23%)

Cost of goods sold

132.7k107.5k131.1k245.5k131.0k91.5k

Gross profit

270.6k261.8k183.6k410.9k215.9k174.0k

Gross profit Margin, %

67%71%58%63%62%66%

Sales and marketing expense

97.7k33.2k171.1k125.7k127.1k90.1k

R&D expense

58.1k

General and administrative expense

702.5k865.1k1.6m1.5m1.4m960.0k

Operating expense total

1.7m1.3m3.2m2.2m2.2m1.5m

EBIT

(1.5m)(1.1m)(3.0m)(1.8m)(2.0m)(1.3m)

EBIT margin, %

(365%)(293%)(944%)(274%)(584%)(494%)

Interest expense

338.9k262.9k144.7k

Interest income

192.04.2k9.9k

Pre tax profit

(1.7m)

Income tax expense

Net Income

(1.7m)(1.3m)(3.1m)(2.3m)(2.3m)(1.4m)

Entia Biosciences Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

16.6k13.1k36.9k99.5k24.1k76.1k

Accounts Receivable

36.3k62.4k11.2k243.8k7.1k8.0k

Prepaid Expenses

31.9k32.5k34.5k46.1k56.8k

Inventories

173.6k132.1k138.9k95.4k40.3k69.8k

Current Assets

258.4k244.2k225.5k484.7k128.3k234.3k

PP&E

31.8k35.6k62.1k43.1k32.7k18.3k

Total Assets

404.9k463.0k631.1k870.7k448.6k439.1k

Accounts Payable

331.8k654.9k1.2m569.2k960.6k1.4m

Short-term debt

23.2k2.8k25.9k51.0k97.3k62.2k

Current Liabilities

599.7k1.1m1.6m987.2k1.2m2.1m

Long-term debt

2.1k62.2k

Non-Current Liabilities

65.0k2.1k

Total Debt

23.2k4.9k47.6k102.1k78.1k124.4k

Total Liabilities

664.7k1.1m1.6m987.2k1.2m2.4m

Common Stock

7.2k7.4k8.3k15.5k28.1k

Preferred Stock

44.0110.0282.0201.0191.0

Additional Paid-in Capital

4.3m5.1m7.8m10.8m12.3m12.5m

Retained Earnings

(4.0m)(5.3m)(8.5m)(10.8m)(13.1m)(14.5m)

Total Equity

(259.8k)(648.3k)(949.6k)(116.5k)(791.2k)(2.0m)

Debt to Equity Ratio

-0.1 x0 x-0.1 x-0.9 x-0.1 x-0.1 x

Debt to Assets Ratio

0.1 x0 x0.1 x0.1 x0.2 x0.3 x

Financial Leverage

-1.6 x-0.7 x-0.7 x-7.5 x-0.6 x-0.2 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016

Cash

11.3k8.0k8.0k18.0k14.7k33.4k13.2k45.4k23.1k15.5k85.6k179.1k182.0k41.4k17.8k2.0k

Accounts Receivable

45.4k44.1k8.4k35.3k26.6k75.7k81.3k93.3k36.2k30.8k65.7k14.0k48.0k53.1k9.5k10.0k5.7k

Prepaid Expenses

14.9k12.9k22.6k14.0k10.0k29.6k18.1k13.5k28.6k23.0k19.1k33.1k20.8k15.1k45.0k41.1k36.2k

Inventories

143.7k179.5k180.7k167.5k158.7k118.7k107.5k128.4k127.5k113.1k116.8k121.3k123.7k117.8k31.2k13.1k28.7k

Current Assets

223.1k260.3k219.7k234.7k209.9k263.9k225.1k285.1k216.3k183.6k287.1k351.5k374.6k227.4k85.7k81.9k72.6k

PP&E

39.5k35.9k29.5k42.6k38.2k60.5k61.9k72.1k56.2k52.8k48.6k37.7k38.8k36.3k29.1k25.4k21.8k

Total Assets

353.2k405.3k396.2k441.1k417.7k517.5k622.0k703.6k616.0k579.5k669.4k736.6k758.4k609.1k405.8k399.8k365.8k

Accounts Payable

255.9k290.6k423.1k485.2k549.2k816.9k800.5k911.5k1.3m1.3m558.0k675.6k674.3k761.9k1.1m1.3m1.5m

Short-term debt

1.6k3.9k13.8k2.8k2.8k2.1k1.4k144.9k45.4k33.5k29.8k42.6k9.0k5.5k96.6k80.9k74.1k

Current Liabilities

669.2k774.8k748.0k543.7k918.5k1.3m1.3m1.4m1.8m1.9m1.2m1.1m840.7k900.4k1.3m1.5m1.7m

Long-term debt

3.5k2.6k2.1k2.1k2.1k15.6k

Non-Current Liabilities

65.0k333.0k63.0k2.1k2.1k2.1k15.6k297.2k298.6k

Total Debt

1.6k3.9k13.8k6.3k5.4k4.2k3.5k288.5k88.0k66.1k59.5k42.6k17.9k11.0k73.2k42.0k28.2k

Total Liabilities

669.2k774.8k813.0k876.7k981.6k1.3m1.3m1.4m1.8m1.9m1.2m1.1m840.7k900.4k1.4m1.8m2.0m

Common Stock

62.0k62.2k7.2k7.2k7.4k7.4k7.6k7.8k8.4k9.1k13.2k16.9k27.5k29.1k28.1k28.1k28.1k

Preferred Stock

22.042.063.085.089.0150.0241.0270.0282.0238.0208.0201.0193.0191.0188.0188.0188.0

Additional Paid-in Capital

2.8m3.0m4.4m4.7m4.9m5.4m6.4m7.0m8.1m8.4m9.7m11.1m12.4m12.5m12.3m12.4m12.4m

Retained Earnings

(3.2m)(3.4m)(4.4m)(4.8m)(5.0m)(5.8m)(6.8m)(7.4m)(9.1m)(9.6m)(10.1m)(11.3m)(12.4m)(12.8m)(13.3m)(13.8m)(14.0m)

Total Equity

(316.0k)(369.4k)(416.8k)(435.6k)(563.8k)(758.1k)(692.9k)(679.6k)(1.2m)(1.3m)(567.9k)(318.7k)(82.3k)(291.3k)(1.0m)(1.4m)(1.6m)

Debt to Equity Ratio

0 x0 x0 x0 x0 x0 x0 x-0.4 x-0.1 x0 x-0.1 x-0.1 x-0.2 x0 x-0.1 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0 x0 x0.4 x0.1 x0.1 x0.1 x0.1 x0 x0 x0.2 x0.1 x0.1 x

Financial Leverage

-1.1 x-1.1 x-1 x-1 x-0.7 x-0.7 x-0.9 x-1 x-0.5 x-0.4 x-1.2 x-2.3 x-9.2 x-2.1 x-0.4 x-0.3 x-0.2 x

Entia Biosciences Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(1.7m)(1.3m)(3.1m)(2.3m)(2.3m)(1.4m)

Depreciation and Amortization

15.1k21.5k36.0k38.0k32.0k17.7k

Accounts Receivable

6.1k26.1k30.7k(262.6k)236.7k(875.0)

Inventories

(4.5k)(18.0k)15.8k43.6k53.025.6k

Accounts Payable

248.4k323.1k661.2k766.1k553.8k412.9k

Cash From Operating Activities

(208.7k)(314.6k)(766.7k)(680.3k)(536.6k)(715.1k)

Purchases of PP&E

3.7k17.2k(4.6k)(8.1k)

Cash From Investing Activities

(31.1k)(63.3k)(64.6k)(45.5k)(21.3k)(7.1k)

Short-term Borrowings

(43.2k)(177.7k)

Cash From Financing Activities

191.4k374.4k855.1k788.3k482.5k774.1k

Net Change in Cash

(48.4k)(3.6k)23.8k62.6k(75.3k)51.9k

Interest Paid

1.7k5.6k1.1k843.037.8k6.7k

Income Taxes Paid

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016

Net Income

(894.1k)(1.1m)(321.8k)(693.8k)(974.6k)(453.5k)(1.5m)(2.0m)(535.4k)(1.0m)(1.6m)(520.5k)(1.6m)(2.0m)(272.6k)(674.2k)(963.0k)

Depreciation and Amortization

7.4k11.0k4.9k11.1k16.3k6.0k14.4k25.1k9.8k19.7k56.3k8.8k17.5k25.0k4.7k9.5k14.2k

Accounts Receivable

12.8k11.4k(27.9k)(1.0k)(9.7k)13.3k18.9k30.9k25.0k19.6k54.5k229.8k195.7k190.7k(2.4k)(2.9k)1.4k

Inventories

(12.3k)23.5k7.2k(6.1k)(14.9k)(13.4k)(24.7k)(3.7k)(11.5k)(25.9k)(22.2k)(25.9k)(28.3k)(22.4k)9.1k27.2k31.7k

Accounts Payable

86.8k95.0k91.3k153.3k217.4k162.7k365.5k541.6k196.5k196.2k404.8k98.1k236.3k323.6k124.1k352.6k509.7k

Cash From Operating Activities

(69.2k)(185.7k)(59.4k)(123.5k)(169.8k)(120.1k)(314.4k)(489.8k)(91.7k)(257.4k)(402.3k)14.1k(310.5k)(477.1k)(99.2k)(201.5k)(275.1k)

Purchases of PP&E

3.7k3.7k1.7k14.0k14.9k30.8k38.1k(6.4k)(8.1k)

Cash From Investing Activities

(14.5k)(30.2k)(34.9k)(64.7k)(72.2k)(41.6k)(43.2k)(75.5k)(3.8k)(10.0k)(32.9k)(8.0k)(15.4k)(20.8k)(4.5k)(7.1k)(7.1k)

Short-term Borrowings

(61.5k)(161.6k)(170.4k)(15.4k)(31.0k)(43.7k)

Cash From Financing Activities

29.9k158.8k85.6k189.5k240.1k182.1k357.7k597.6k81.8k246.0k484.0k73.5k408.4k439.8k79.6k202.3k260.1k

Net Change in Cash

(53.8k)(57.1k)(8.6k)1.3k(1.9k)20.3k80.032.3k(13.7k)(21.4k)48.7k79.7k82.6k(58.1k)(24.1k)(6.4k)(22.1k)

Interest Paid

1.7k1.7k274.0725.0893.0581.0770.0906.0758.0840.0843.016.6k36.0k36.2k1.8k5.7k6.7k

Income Taxes Paid

Entia Biosciences Ratios

USDQ2, 2011

Financial Leverage

-1.1 x